2月18日,Tempus AI飙升逾8%!该公司宣布推出其新型HRD-RNA癌症检测算法。与传统DNA检测不同,Tempus基于RNA的方法通过分析基因表达而非结构性DNA损伤,提供对肿瘤功能状态的实时评估。这种方法使该模型能够在基因组瘢痕难以识别的患者和癌症类型中检测出HRD。据该公司称,一项真实世界验证研究显示,接受一线铂类治疗方案的HRD-RNA阳性转移性胰腺癌患者,与接受非铂类一线治疗的患者相比,死亡风险显著降低。完整的支持数据将于今年晚些时候发表。
2月18日,Tempus AI飙升逾8%!该公司宣布推出其新型HRD-RNA癌症检测算法。与传统DNA检测不同,Tempus基于RNA的方法通过分析基因表达而非结构性DNA损伤,提供对肿瘤功能状态的实时评估。这种方法使该模型能够在基因组瘢痕难以识别的患者和癌症类型中检测出HRD。据该公司称,一项真实世界验证研究显示,接受一线铂类治疗方案的HRD-RNA阳性转移性胰腺癌患者,与接受非铂类一线治疗的患者相比,死亡风险显著降低。完整的支持数据将于今年晚些时候发表。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.